Recommendation of the President – Abecma (idecabtagene vicleucel)
On 31 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 106/2025 on the inclusion of the medicinal product Abecma (idecabtagene vicleucel) in the drug program B.54 Treatment of patients with multiple myeloma (ICD-10: C90.0)